| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:00 | Ondine Biomedical - New Independent Study Supports Photodisinfection | - | RNS | ||
| 23.12.25 | Ondine Biomedical - Finalist for 2nd National Award for SSI reduction | - | RNS | ||
| 22.12.25 | Ondine Biomedical - First German Hospital Pilots Steriwave | - | RNS | ||
| 16.12.25 | Ondine Biomedical - Ondine shortlisted for HSJ Partnership Award | - | RNS | ||
| 27.10.25 | Ondine Biomedical - Topline Results Significant in Steriwave ICU Study | 4 | RNS | ||
| 02.10.25 | Ondine Biomedical - Cambridge's Papworth Hospital Pilots Steriwave | 1 | RNS | ||
| 26.09.25 | UK Stock Market News: Pennon, Seeing Machines, Ondine | 6 | The Armchair Trader | ||
| 26.09.25 | Ondine Biomedical - Ondine Biomedical Continues Growth in H1 2025 | 1 | RNS | ||
| ONDINE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 23.09.25 | Ondine Biomedical - Steriwave Now Protecting Patients with Cancer | - | RNS | ||
| 19.09.25 | Ondine Biomedical - Notice of Interim Results & Investor Presentation | - | RNS | ||
| 18.09.25 | Ondine reports 70% reduction in surgical site infections with Steriwave | 2 | Investing.com | ||
| 18.09.25 | Ondine: Steriwave senkt postoperative Wundinfektionen um 70 % | 2 | Investing.com Deutsch | ||
| 18.09.25 | Ondine Biomedical - Ondine Presents Major Economic Benefits at ICPIC | - | RNS | ||
| 15.09.25 | Ondine Biomedical - Steriwave proven to be effective against C Auris | - | RNS | ||
| 12.09.25 | Ondine Biomedical - Grant of Options | - | RNS | ||
| 10.09.25 | Ehemaliger Präsident Fox wirbt auf CNBC für Desinfektionstechnologie von Ondine | 2 | Investing.com Deutsch | ||
| 10.09.25 | Ondine's nasal disinfection technology featured on CNBC program | 1 | Investing.com | ||
| 10.09.25 | Ondine Biomedical - Steriwave Featured on CNBC's Worldwide Exchange | - | RNS | ||
| 08.09.25 | Ondine Biomedical - Notification of major holdings - hInsight | - | RNS | ||
| 04.09.25 | Pentwater Capital Management increases stake in Ondine Biomedical | 3 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,415 | -1,26 % | QIAGEN - hält was es verspricht | Das Unternehmen aus Hilden hat seine Prognosen im abgelaufenen Geschäftsjahr erreicht. Nun geht es optimistisch in das neue Jahr, in dem es sich auf die Förderung der Produktvermarktung, regulatorische... ► Artikel lesen | |
| BIONTECH | 91,70 | +4,80 % | +23 % Kursplus in wenigen Tagen! DroneShield, BioNTech, WashTec Aktie! | Über 23 % hat die Aktie von DroneShield in den ersten Handelstagen des Jahres bereits zulegen können. Rückenwind erhält der Spezialist für Drohnenabwehr durch zwei Aufträge kurz vor dem Jahreswechsel.... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 81,95 | +18,15 % | Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight | ||
| PRAXIS PRECISION MEDICINES | 273,87 | -0,72 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| ALUMIS | 22,590 | +7,11 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,630 | -2,41 % | Citizens reiterates Market Outperform rating on Summit Therapeutics stock | ||
| ERASCA | 6,445 | +3,45 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,515 | +2,20 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| EVOTEC | 6,552 | +1,36 % | Evotec Aktie: Das große Comeback im Jahr 2026? | Nächster Anlauf der Evotec Aktie auf große charttechnische Kaufsignale - bisher misslangen diese Ausbruchsversuche. Nachdem die Biotech-Aktie in den letzten Tagen zunächst an der Unterstützung bei 5... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,34 | -0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BEAM THERAPEUTICS | 33,690 | 0,00 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,650 | -3,73 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 10,740 | -5,21 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| CG ONCOLOGY | 53,55 | -0,34 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,900 | -3,18 % | Dyne Therapeutics, Inc. - 8-K, Current Report |